Retinal changes in COVID-19 hospitalized cases

Rafael Lani-Louzada1, Carolina do Val Ferreira Ramos2, Ricardo Mello Cordeiro3,4, Alfredo A. Sadun5

1 Hospital Nossa Senhora da Saúde, Santa Casa da Misericórdia do Rio de Janeiro (Hospital da Gamboa), Instituto de Ofalmologia do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, 2 Clínica Nossa Senhora da Paz, Rio de Janeiro, Rio de Janeiro, Brazil, 3 Departamento de Clínica Médica, Hospital de Clínicas de Jacarepaguá, Rio de Janeiro, Rio de Janeiro, Brazil, 4 Departamento de Clínica Médica, Hospital de Clínicas Mário Lioni, Rio de Janeiro, Rio de Janeiro, Brazil, 5 Department of Ophthalmology, David Geffen School of Medicine at UCLA, Doheny Eye Institute, Los Angeles, California, United States of America

* rafalani.md@gmail.com

Abstract

The main objective of this study was to evaluate the retinas of severely or critically ill COVID-19 patients during their hospital stay, at varying time points after symptoms onset. This was a case series observed during May 2020 in two referral centers for COVID-19 treatment in Rio de Janeiro, Brazil. 47 eyes from 25 hospitalized patients with severe or critical confirmed illness were evaluated. A handheld retinal camera was used to acquire bilateral fundus images at several time points after symptoms onset. Electronic health records were retrospectively analyzed and clinical data collected. Severe and critical diseases were noticed in 52% (13/25) and 48% (12/25) of enrolled patients, respectively. Retinal changes were present in 12% (3/25) of patients: a 35 year-old male demonstrated bilateral nerve fiber layer infarcts and microhemorrhages in the papillomacular bundle, but required mechanical ventilation and developed severe anemia and systemic hypotension, acute kidney injury and neurologic symptoms during the course of the disease (critical illness); a 56 year-old male, who required full enoxaparin anticoagulation due to particularly elevated D-dimer (>5.0 mcg/mL), demonstrated unilateral and isolated flame-shaped hemorrhages; and a 49 year-old hypertensive male showed bilateral and discrete retinal dot and blot microhemorrhages. The other 22 patients evaluated did not demonstrate convincing retinal changes upon examination. There was no correlation between disease severity and admission serum levels of CRP, D-dimer and ferritin. This was the first study to show that vascular retinal changes may be present in not insignificant numbers of severe or critical COVID-19 inpatients. These retinal changes, only seen after morbid developments, were likely secondary to clinical intercurrences or comorbidities instead of a direct damage by SARS-CoV-2, and may be important and easily accessible outcome measures of therapeutic interventions and sentinels of neurologic and systemic diseases during COVID-19 pandemic.
Introduction

The novel coronavirus disease in 2019 (COVID-19) has been responsible for over 16 million confirmed cases worldwide, with more than 800,000 confirmed deaths [1]. The respiratory symptoms that characterize COVID-19 [2, 3] may be associated with a wide range of neurological complications, including cerebrovascular diseases (acute ischemic infarcts in small or large arterial vessels, cerebral venous sinus thrombosis and intracranial hemorrhage), usually related to severe or critical disease phenotypes, and which may significantly contribute to patients morbidity and mortality [4]. However, the pathophysiology behind COVID-19 associated brain damage is still poorly understood [5], and both a direct viral neurotropism or indirect mechanisms involving dysregulated inflammatory cytokines release (“cytokine storm”), vascular endothelial injury and hypercoagulation cascades triggering/ disseminated intravascular coagulation are under investigation [4, 6].

Genomic and structural analyses have reported that one of the major players for SARS-CoV-2 entry into the host cell is the cell surface enzyme protein angiotensin-converting enzyme 2 (ACE2), which acts as the functional receptor for SARS-CoV-2 to bind to host cells, followed by cellular transmembrane protease serine 2 (TMPRSS2) for priming [7, 8]. In humans, ACE2 is present in the CNS, lungs, kidney, enterocytes, nose, liver, immune system and blood vessels [9, 10]. In the human eye, this protein has been observed in cornea, conjunctiva [11], aqueous humor [12] and retina [13]. Indeed, evidence of an intraocular renin-angiotensin system regulating important aspects of ocular physiology (e.g. retinal vascular tone and aqueous dynamic) has been demonstrated [12, 14], and viral ribonucleic acid has been detected by reverse transcription polymerase chain reaction (RT-PCR) in retinal biopsies of deceased COVID-19 patients [15], which together endorses the rationale for an ophthalmological syndrome of COVID-19, with some pathophysiology still unknown.

John Dowling referred to the human retina as “the approachable part of the brain” [16], and it’s complex neuronal and vascular milieu can be clinically visualized with proper instruments. Thus, a comprehensive depiction of the ocular fundus from hospitalized SARS-CoV-2 patients, with consideration of distinct disease stages and severity, may lead to further insights on the CNS pathology associated with this novel and challenging disease.

The present study was designed to evaluate the retinas of confirmed COVID-19 patients admitted to hospital units for clinical stabilization and oxygen supplementation, presenting with severe or critical disease, at varying time points after symptoms onset and to measure these changes in reference to interventions and complications.

Materials and methods

Study oversight

A transversal and observational study was conducted during May 2020 in accordance with the tenets of the Declaration of Helsinki and with ethics approval by the Committee of Ethics in Research from Amil Clinical Research board. Patients from two referral centers for COVID-19 treatment in Rio de Janeiro, Brazil, were recruited and gave written informed consent before fundus examination.

Study inclusion criteria included subjects hospitalized for clinical instability caused by COVID-19 who were able to provide informed consent, or with a legal representative able to provide informed consent in the name of the participant. Participants were confirmed cases of COVID-19, which was defined as a positive result on reverse-transcriptase polymerase chain reaction (RT-PCR) assay of nasal swab specimens. Exclusion criteria were patients with
negative RT-PCR for SARS-CoV-2 on nasal swab specimens, and patients with previously diagnosed retinal diseases such as moderate/severe diabetic retinopathy or optic neuropathies.

**Participants and study procedures**

In total, 47 eyes from 25 inpatients from two referral centers for COVID-19 treatment in Rio de Janeiro, Brazil, were enrolled in the study. Electronic health records were retrospectively analyzed and clinical data collected including age, gender, symptoms and day after symptoms onset for hospitalization, admission serous levels of D-dimer, ferritin and C-reactive protein (CRP), day after symptoms onset ophthalmological examination, extension of ground-glass opacities on chest CT and systemic comorbidities.

Cases were classified as severe or critical according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia Trial Version 7, released by the National Health Commission & National Administration of Traditional Chinese Medicine on March 3rd, 2020 [17]. Briefly, severe cases included patients with radiological findings of viral pneumonia and clear respiratory distress, characterized by respiratory rate $\geq 30$ breaths/minute, or oxygen saturation $\leq 93\%$ at rest; critical cases were those requiring continuous monitoring in intensive care units (ICU) for the eminent risk of hypoxemia and respiratory failure, as well as patients with indications for invasive mechanical ventilation, diagnosis of shock or any other organ failure requiring ICU care.

Ocular fundi were evaluated by using a handheld digital retinal camera connected with a smartphone, with nine internal points of gaze fixation for central and peripheral retinal imaging (Phelcom Eyer; Phelcom Technologies, Sao Paulo, Brazil). The procedure was performed in a bedside manner. The examiner (RL) wore proper personal protective equipment including inner and outer gloves, fit-tested N95 mask plus medical mask, gown and goggle [18]. For better retinal documentation, most patients had their pupils pharmacologically dilated by topical instillation of tropicamide 10 mg/mL eye drops.

The retinal camera automatically registered both colored and red-free retinographies in each acquisition. Retinal images were sent to a cloud server (EyerCloud; Phelcom Technologies, Sao Paulo, Brazil) and independently analyzed by two researchers (RL and CVFR), who were masked as to the patients’ blood parameters and medical history.

**Statistical analysis**

Statistical analysis was performed using GraphPad Prism 6.0c software. Data are expressed as mean $\pm$ STD. Unpaired two-tailed T-Student test was done to compare the blood parameters mean values of severe and critical disease groups, as well as the mean age and days post symptoms onset for hospital admission and fundus examination. Two-tailed Fisher’s exact test was done to compare proportions (gender, symptoms, past medical history and retinal changes). $P$-values less than 0.05 were considered statistically significant.

**Results**

**Demographic and clinical characteristics**

Among participants, 64% were men, 36% were women, varying in age between 35 and 75 years (mean $\pm$ STD: 51.2 $\pm$ 10.8 years). All patients tested positive for SARS-CoV-2 on RT-PCR performed on nasal swab specimens. Regarding disease severity, since all patients required hospitalization for clinical stability, no patients enrolled in the study was classified with mild disease (Table 1). Also, no patient classified as moderate since oxygen supplementation was necessary
to all patients in order to maintain normal oxygen levels. Severe disease was noticed in 13 out of 25 patients (52%) during ophthalmic examination. Finally, 48% patients in our study (12/25) presented critical disease requiring ICU monitorization at some moment during their hospital stay (Table 1). Among them, 67% (8/12) needed mechanical ventilation through an endotracheal tube or tracheostomy, and 33% (4/12) required high-flow oxygen therapy (9–10L/min) delivered using a Venturi mask.

Among symptoms typically found in COVID-19, we observed dyspnea (88%), cough (84%), fever (80%), myalgia (56%), fatigue (32%), headache (24%), nasal congestion (16%),

### Table 1. General and demographic characteristics from enrolled population.

| Parameter                  | Total | Disease phenotype | P-value (severe vs critical) |
|----------------------------|-------|-------------------|-----------------------------|
|                            |       | Severe            | Critical                    |                             |
| Percentage (number)        |       | 52% (13/25)       | 48% (12/25)                 | NA                          |
| Age (years)                | 35–75 | 38–75             | 35–67                       | 0.1091                      |
|                           | (51.2 ± 10.8)* | (54.5 ± 10.0)* | (47.5 ± 10.9)*            |                             |
| Gender                     |       |                   |                             | 1.0000                      |
| Male (%)                   | 64% (16/25) | 61.5% (8/13)   | 66.7% (8/12)                |                             |
| Female (%)                 | 36% (9/25) | 38.5% (5/13)    | 33.3% (4/12)                |                             |
| Symptoms                   |       |                   |                             |                             |
| Dyspnea                    | 88% (22/25) | 84.6% (11/13)   | 91.6% (11/12)               | 1.0000                      |
| Cough                      | 84% (21/25) | 76.9% (10/13)   | 91.6% (11/12)               | 0.5930                      |
| Fever                      | 80% (20/25) | 84.6% (11/13)   | 75.0% (9/12)                | 0.6447                      |
| Myalgia                    | 56% (14/25) | 61.3% (8/13)    | 50.0% (6/12)                | 0.6951                      |
| Fatigue                    | 32% (8/25) | 30.8% (4/13)    | 33.3% (4/12)                | 1.0000                      |
| Headache                   | 24% (6/25) | 23.1% (3/13)    | 25.0% (3/12)                | 1.0000                      |
| Nasal Congestion           | 16% (4/25) | 7.7% (1/13)     | 25.0% (3/12)                | 0.3217                      |
| Anosmia                    | 8% (2/25)  | 0% (0/13)        | 16.7% (2/12)                | 0.2200                      |
| Ageusia                    | 8% (2/25)  | 0% (0/13)        | 16.7% (2/12)                | 0.2200                      |
| Nausea                     | 4% (1/25)  | 7.7% (1/13)     | 0% (0/12)                   | 1.0000                      |
| Odynophagia                | 4% (1/25)  | 0% (0/13)        | 8.3% (1/12)                 | 0.4800                      |
| Hyporexia                  | 4% (1/25)  | 7.7% (1/13)     | 0% (0/12)                   | 1.0000                      |
| Rhinorrhea                 | 4% (1/25)  | 7.7% (1/13)     | 0% (0/12)                   | 1.0000                      |
| Days post symptoms onset   |       |                   |                             |                             |
| Hospital admission         | 2–14 (8.6 ± 3.0)* | 2–14 (8.8 ± 3.5)* | 5–14 (8.3 ± 2.6)*             | 0.6876                      |
| Fundus examination         | 10–64 (23.9 ± 14.2)* | 10–22 (15.3 ± 3.5)* | 14–64 (33.25 ± 15.6)* | 0.0021                      |
| Past Medical History       |       |                   |                             |                             |
| Arterial Hypertension      | 60% (15/25) | 53.9% (7/13)    | 66.7% (8/12)                | 0.6882                      |
| Diabetes                   | 32% (8/25) | 30.8% (4/13)    | 33.3% (4/12)                | 1.0000                      |
| Obesity                    | 32% (8/25) | 23.1% (3/13)    | 41.7% (5/12)                | 0.4110                      |
| None                       | 24% (6/25) | 30.8% (4/13)    | 16.7% (2/12)                | 0.6447                      |
| Asthma                     | 4% (1/25)  | 7.7% (1/13)     | 0% (0/12)                   | 1.0000                      |
| Cancer                     | 4% (1/25)  | 7.7% (1/13)     | 0% (0/12)                   | 1.0000                      |
| COPD                       | 4% (1/25)  | 0% (0/13)        | 8.3% (1/12)                 | 0.4800                      |
| Hypothyroidism             | 4% (1/25)  | 0% (0/13)        | 8.3% (1/12)                 | 0.4800                      |
| Retinal changes            | 12% (3/25) | 15.4% (2/13)    | 8.3% (1/12)                 | 1.0000                      |

COPD = Chronic Obstructive Pulmonary Disease

*Mean ± STD; NA: Not Applicable.

https://doi.org/10.1371/journal.pone.0243346.t001
anosmia (8%), ageusia (8%), nausea (4%), odynophagia (4%), hyporexia (4%) and rhinorrhea (4%) (Table 1).

In terms of pre-existing medical conditions, 60% had arterial hypertension; 32% and 28% were diabetic or obese, respectively; 24% had no comorbidities; asthma, cancer, chronic obstructive pulmonary disease (COPD) and hypothyroidism were present in 4% patients each (Table 1). In this study, COVID-19 patients admitted to the inpatient unit during the acute phase were offered a standard treatment based on intravenous azithromycin, amoxicillin clavulanate and hydroxychloroquine, as well as a single dose of oral ivermectin and daily subcutaneous enoxaparin.

A total of four outcome data were evaluated: the one main outcome was retinal changes suggestive of ongoing pathological process; the other three secondary outcomes were comparisons between the two disease severity groups with regard to admission serum level of c-reactive protein (CRP), D-dimer and ferritin.

**Laboratory and imaging on admission**

The mean ± STD of C-reactive protein (CRP) on hospital admission was 12.51 ± 6.94 mg/dL (reference value: <1.0 mg/dL), while D-dimer and ferritin were 1.53 ± 0.99 mcg/mL (reference value: <0.5 mcg/mL; missing data: 1/25 participant) and 1495 ± 921.74 ng/mL (reference value: 11–307 ng/mL; missing data: 3/25 participants), respectively. When correlated with disease severity, the admission blood parameters analyzed did not show statistically significant differences when comparing patients with severe or critical disease [(CRP–Severe: 10.85 ± 6.74 mg/dL, N = 11 vs Critical: 14.88 ± 7.06 mg/dL, N = 12; p = 0.18); (D-dimer–Severe: 1.43 ± 0.93 mcg/mL, N = 11 vs Critical: 1.70 ± 1.06 mcg/mL, N = 12; p = 0.53); (Ferritin–Severe: 917.00 ± 654.96 ng/mL, N = 11 vs 1677.43 ± 1276.21 ng/mL, N = 10; p = 0.71)].

On chest CT scan, 46% (6/13) of patients with severe disease presented on hospital admission with bilateral ground glass opacities in 25–50% of lung parenchyma, while 15% (2/13) had >50% extension, and 38% (5/13) had >50% lung compromise; and one patient with critical disease did not have chest CT scan performed on admission to hospital setting. See Table 2 for detailed description of clinical features from each patient enrolled in the study.

**Retinal analysis**

Patients were admitted to our hospital facility on average after 8.6 ± 3.0 days of symptoms onset, ranging between 2 to 14 days. The fundus examination was performed from 10 to 64 days after beginning of symptoms, with a mean of 23.9 ± 14.2 days (Tables 1 and 2).

Most patients (21/25) permitted the examination of their retina with pharmacological dilation of the pupils using tropicamide 10 mg/mL eye drop. Both eyes were examined in 23 out of 25 patients. Fundus examination was performed with an Eyer portable retinographer (See Materials and methods Section).

Patient #6 was a 35 year–old hypertensive and obese man, who presented ground-glass peripheral opacities occupying 25–50% of the lung parenchyma at admission lung CT scan, progressing 15 days later to 50%. His blood parameters on admission were CRP 6.1 mg/dL, D-dimer 0.27 mcg/mL (Table 2). Retinal examination was performed on day 59 post symptom onset, showing nerve fiber layer infarcts in both eyes, adjacent to the optic nerve head in the right eye (Fig 1A) and close to the inferior temporal vasculature in the left (Fig 1B). Upon
| Patient number | Age (years) | Sex | Symptoms on admission | Hospital admission: days from symptoms onset | Fundus examination: days from symptoms onset | Blood parameter on admission or early hospital stay | Extension of COVID-19 pulmonary findings on chest CT | COVID-19 severity | Complication during hospitalization | Systemic comorbidities |
|----------------|-------------|-----|-----------------------|---------------------------------------------|---------------------------------------------|------------------------------------------------|--------------------------------------------------|-------------------|---------------------------------------|-----------------------|
| #1             | 75          | Female | Fever, cough, myalgia, dyspnea | 7                                           | 12                                          | 17.7                                            | 1.86                                            | 1025.0             | 25–50%                  | Severe; None Arterial hypertension; Diabetes Mellitus; Metastatic cancer |
| #2             | 47          | Female | Fever, cough, headache, nausea, fatigue | 10                                          | 13                                          | 8.7                                             | NA                                              | NA                | 25–50%                  | Severe; None Arterial hypertension; Diabetes Mellitus |
| #3             | 48          | Male   | Cough, nasal congestion, myalgia, dyspnea | 14                                          | 17                                          | 2.2                                             | 2.83                                            | 1199.0             | 25–50%                  | Severe; None Obesity |
| #4             | 50          | Male   | Fever, cough, myalgia, dyspnea | 9                                           | 12                                          | 15.9                                            | 1.34                                            | 1845.0             | >50%                    | Severe; None None |
| #5             | 48          | Male   | Fever, cough, fatigue, dyspnea | 8                                           | 47                                          | 24.1                                            | 2.08                                            | >1620.0            | >50%                    | Critical; Respiratory failure requiring mechanical ventilation/ ICU Arterial hypertension |
| #6             | 35          | Male   | Fever, cough, dyspnea | 7                                           | 64                                          | 6.1                                             | 0.27                                            | NA                | 25–50%                  | Critical; Respiratory failure requiring mechanical ventilation/ ICU/ Acute kidney injury/ ICU/ Neuromyopathy of critical illness Arterial hypertension; Obesity; Hypothyroidism |
| #7             | 67          | Male   | Cough and dyspnea | 7                                           | 46                                          | 15.1                                            | 0.55                                            | >1650.0            | >50%                    | Critical; Respiratory failure requiring mechanical ventilation/ ICU Arterial hypertension |
| #8             | 37          | Male   | Fever, cough, nasal congestion, myalgia, fatigue, dyspnea | 5                                           | 18                                          | 10.3                                            | 1.13                                            | 1373.0             | 25%                     | Critical; Respiratory failure/ ICU None |
| #9             | 60          | Male   | Fever, myalgia, fatigue, diarrhea, dyspnea | 8                                           | 18                                          | 16.6                                            | 0.7                                             | 2558.0             | 25–50%                  | Severe; None Arterial hypertension |
| #10            | 63          | Male   | Fever, cough, myalgia, dyspnea | 6                                           | 10                                          | 10.8                                            | 2.15                                            | 1346.0             | 50%                     | Severe; None Arterial hypertension; Diabetes Mellitus |
| #11            | 43          | Male   | Fever, cough, headache, dyspnea | 9                                           | 18                                          | 2.8                                             | 0.35                                            | 1534.0             | >50%                    | Severe; None Asthma |
| #12            | 51          | Female | Cough, fatigue, dyspnea, ageusia | 9                                           | 15                                          | 15.8                                            | 0.71                                            | 280.4              | >50%                    | Critical; Respiratory failure/ ICU Arterial hypertension; Diabetes Mellitus; Obesity; COPD |

(Continued)
| Patient number | Age (years) | Sex | Symptoms on admission                                                                 | Hospital admission: days from symptoms onset | Fundus examination: days from symptoms onset | Blood parameter on admission or early hospital stay | Extension of COVID-19 pulmonary findings on chest CT | COVID-19 severity | Complication during hospitalization | Systemic comorbidities                                                                 |
|----------------|-------------|-----|---------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------------------|-------------------------------------------------|-------------------|--------------------------------------|-------------------------------------------------------------------------------------|
| #13            | 57          | Male | Fever, fatigue, dyspnea                                                               | 14                                             | 18                                            | 22.9, 1.0, 1993.0                                 | 75%                                             | Severe            | None                                 | None                                                                |
| #14            | 38          | Female | Cough, fever, rhinorrhea, myalgia, dyspnea                                             | 10                                             | 18                                            | 6.2, 0.55, 50.86                                 | >50%                                           | Severe            | None                                 | None                                                                |
| #15            | 59          | Male | Fever, cough, odynophagia, myalgia                                                     | 10                                             | 39                                            | 8.6, 1.38, NA                                    | >50%                                           | Critical          | Respiratory failure/ ICU              | Diabetes Mellitus                                                                 |
| #16            | 59          | Female | Fever, hyporexia, fatigue                                                             | 5                                              | 22                                            | 6.8, 0.71, 592.0                                 | 25–50%                                         | Severe            | None                                 | Arterial hypertension; Diabetes Mellitus; Obesity                               |
| #17            | 64          | Female | Cough, dyspnea                                                                         | 2                                              | 13                                            | 11.5, 1.64, 272.0                                 | >50%                                           | Severe            | None                                 | Arterial hypertension; Obesity                                                   |
| #18            | 56          | Male | Fever, cough, headache, myalgia, dyspnea                                               | 13                                             | 16                                            | 12.1, 5.92, 1030.0                               | 50%                                            | Severe            | None                                 | Arterial hypertension                                                            |
| #19            | 49          | Male | Fever, cough, myalgia, dyspnea                                                         | 8                                              | 12                                            | 6.8, 0.27, 1774.0                                | 25–50%                                         | Severe            | None                                 | Arterial hypertension                                                            |
| #20            | 42          | Female | Fever, cough, headache, myalgia, dyspnea                                               | 5                                              | 14                                            | 9.0, 0.93, 647.0                                 | Critical                                       | Respiratory failure/ ICU              | Arterial hypertension; Obesity                                                   |
| #21            | 35          | Female | Fever, cough, dyspnea                                                                  | 10                                             | 47                                            | 22.8, 3.17, 657.0                                | NA                                             | Critical          | Respiratory failure requiring mechanical ventilation/ Acute kidney injury/ ICU | Diabetes Mellitus                                                                 |
| #22            | 62          | Male | Fever, cough, nasal congestion, myalgia, anosmia, ageusia, dyspnea                      | 6                                              | 34                                            | 22.4, 2.79, 1670.0                               | 50%                                            | Critical          | Respiratory failure requiring mechanical ventilation/ acute mesenteric ischemia / ICU | Arterial hypertension; Diabetes Mellitus; Obesity                               |
| #23            | 47          | Female | Fever, cough, headache, nasal congestion, myalgia, dyspnea                             | 14                                             | 21                                            | 4.1, 2.61, 555.0                                 | >50%                                           | Critical          | Respiratory failure requiring mechanical ventilation/ ICU | Arterial hypertension                                                            |
| Patient number | Age (years) | Sex | Symptoms on admission | Hospital admission: days from symptoms onset | Fundus examination: days from symptoms onset | Blood parameter on admission or early hospital stay | Complication during hospitalization | Extension of COVID-19 pulmonary findings on chest CT | COVID-19 severity | Complication during hospitalization | Systemic comorbidities |
|---------------|------------|-----|------------------------|----------------------------------------------|---------------------------------------------|---------------------------------------------------|---------------------------------------|---------------------------------------------|-----------------|---------------------------------------|----------------------|
| #24          | 37         | Male | Fever, headache, myalgia, dyspnea | 10                                           | 29                                           | 20.4, 1.4, 3769.0, 3769.0 | Critical | 50% | Critical                              | Respiratory failure requiring mechanical ventilation/ Acute kidney injury/ Hemorrhagic stroke (subarachnoid and intracerebral hemorrhage) | Arterial hypertension; Obesity |
| #25          | 50         | Male | Cough, anosmia, dyspnea | 8                                           | 25                                           | 19.8, 3.33, 3071.0 | Critical | 50% | Critical                              | Respiratory failure requiring mechanical ventilation (ICU) | None |

NA = Not Applicable
COPD = Chronic Obstructive Pulmonary Disease

https://doi.org/10.1371/journal.pone.0243346.t002
Fig 1. Color and red-free retinal photographs from patient #6 (W.A.C.). Images acquired on day 64 after symptoms onset, from a 35 year-old obese and hypertensive man who was admitted on day seven since onset of fever, cough and dyspnea. During hospitalization, this patient evolved to critical illness, characterized by acute respiratory distress syndrome, respiratory failure and acute kidney injury, requiring ICU monitoring, mechanical ventilation and hemodialysis. The patient had a positive clinical outcome, and received hospital discharge on day 69 after symptoms onset. (A) Right retina showing a nerve fiber layer infarct above the optic nerve head, and microhemorrhages in the papillomacular bundle close to the optic disc. (B) Left retina showing nerve fiber layer infarcts at the inferior temporal vascular arcade, approximately 1.5 disc diameters inferior to the macula. Square and circular insets represent 2x magnification of the delimited area.

https://doi.org/10.1371/journal.pone.0243346.g001
reexamination 5 days later (day 64 shown in Fig 1), there were no changes in terms of intensity or extension of the lesions previously observed. Additionally, discrete microhemorrhages were noticed in the papillomacular bundle in both eyes. He had a critical phenotype of COVID-19, requiring endotracheal intubation and mechanical ventilation in the ICU due to acute respiratory distress syndrome. During the hospital stay, this patient developed hemodynamic instability, with multiple episodes of systemic hypotension requiring continuous catecholamine infusion at high doses, associated with acute renal injury requiring hemodialysis. Moreover, severe and symptomatic anemia was observed, with hemoglobin levels and hematocrits dipping to values below 6.5 g/dL and 21.0%, respectively. Dysesthesia plus flaccid weakness were evident on distal lower and upper limbs, characterized as sensory and motor axonal polyneuropathy on electroneuromyography test and diagnosed as a neuropathy of critical illness by the medical team (Table 2). When ophthalmological examination was performed, this patient was clinically stabilized with normal kidney function.

Patient #18 (Table 2) was a 56 year-old man referred in with no comorbidities. He presented with a unilateral flame-shaped lesion approximately one disc diameter from the optic nerve head, adjacent to the inferior temporal vascular arcade (Fig 2). The contralateral retina had no vascular lesions observed. This patient was admitted 13 days after onset of symptoms (fever, cough, headache, myalgia and dyspnea), had 50% ground-glass opacities bilaterally on pulmonary parenchyma (chest CT scan), and evolved to a severe phenotype but not requiring ICU continuing monitorization or mechanical ventilation. Fundus examination was performed on day 16 after symptoms onset (Table 2). Blood parameters on admission were CRP 12.1 mg/dL, D-dimer 5.92 mcg/mL and ferritin 1030.0 ng/mL (Table 2). Due to particularly high levels of D-dimer during hospitalization, this patient received full anticoagulation with heparin instead of the prophylactic dose routinely used for COVID-19 inpatients.

Patient #19 was a 49 year-old hypertensive man hospitalized on the eighth day after symptoms onset (fever, myalgia and dyspnea). He presented with isolated microhemorrhages in both eyes in the inferior retinal quadrant close to the vascular arcades (Fig 3). Retinal documentation was done on day 12 of symptoms onset. This patient, admitted with altered blood parameters (CRP 6.8 mg/dL; ferritin 1774.0 ng/mL) and abnormal lung CT scan (25–50% ground-glass opacities extension), evolved to a severe COVID-19 phenotype, but not requiring ICU monitorization or mechanical ventilation (Table 2).

None of the other 22 patients enrolled demonstrated overt retinal changes upon careful analysis of both color and red free retinal photographs.

Discussion

Surprisingly, of the 25 patients with severe or critical disease in our study, only three (12%) manifested convincing retinal changes (microhemorrhages, flame-shaped hemorrhage and nerve fiber layer infarcts). Of their six eyes, five showed retinal lesions. These three patients were in late phases of COVID-19 disease (#6: 59 and 64 days of symptoms onset; #18: 16 days; #19: 12 days). As retinal lesions as described in the present study are not uncommon in septic patients with infectious diseases [19], our results underline that comorbidities, clinical intercurrences or the robust immune response are more likely related to the retinal findings, instead of a direct neuronal injury from SARS-CoV-2 as previously suggested in mild to moderate COVID-19 outpatients [20]. Patient #6, for instances, was critical and had severe anemia and hypotension, as well as injury to other organs including kidneys and the peripheral nervous system, which could justify the bilateral nerve fiber layer infarcts and microhemorrhages in the papillomacular bundle found upon dilated retinal examination. Patient #18 presented with high serum levels of D-dimer (>5.0 mcg/mL) and required full dosing of subcutaneous
enoxaparin for anticoagulation leading to higher bleeding risk; associated with intermittent episodes of cough (Valsalva maneuver), one of the patient’s symptoms (Table 2), this could be related with the isolated unilateral flame-shaped hemorrhage shown upon retinal examination. Patient #19, on the other hand, had systemic hypertension, and although hypertensive retinopathy was not apparent, intermittent blood pressure peaks occurred during his hospital stay and there was a likely fragile blood-retinal barrier due to systemic inflammation, as reflected by elevated inflammatory biomarkers on admission (CRP: 6.8 mg/dL; ferritin: 1774 ng/mL)
Genetic factors may have also influenced the emergence of retinal abnormalities in the three patients depicted in the presented study, in contrast to the other 22 patients who did not present any retinal changes upon careful retinographies evaluation, despite the severe or critical disease phenotype with varied related clinical intercurrences during hospitalization.

On the other hand, disease phenotype, per se, does not seem to impact the findings on fundus examination in the present study, as comparison between severe and critical patients showed no statistical significance in terms of retinal changes (Table 1).

Fig 3. Color and red-free retinal photographs from patient #19 (G.C.X.). Images acquired on day 12 from symptoms onset, from a 49 year-old man in regular treatment for arterial hypertension, admitted on the eighth day after onset of fever, cough, myalgia and progressive dyspnea. Lung CT on admission showed typical viral pneumonia findings extending through 25–50% of the parenchyma. The patient evolved to a severe phenotype of the disease. (A) Right retina presenting with isolated microhemorrhage at the periphery close to the inferior temporal vasculature. (B) Left retina showing isolated microhemorrhage at the inferior nasal retinal quadrant. Insets represent delimited areas with 2x magnification.

https://doi.org/10.1371/journal.pone.0243346.g003
Severe pneumonia is the major life-threatening clinical manifestation of COVID-19. This may lead to respiratory distress and lung failure. However, extrapulmonary sites of the disease have been recognized. Various distinct types of neurologic involvements have been reported, such as cerebrovascular diseases, encephalitis, acute necrotizing encephalopathy, meningitis/encephalitis, olfactory and gustatory disorders independent of nasal mucosa inflammation, demyelinating neuropathy (e.g. Guillain-Barré syndrome), cranial polyneuropathies (e.g. Miller Fischer), radiculopathy and large intracerebral artery wall inflammation [21–25]. Some of these may relate to parainfectious processes, hypoxic injury or dysfunctional immune responses mediated by numerous immunomodulatory molecules like IL-6, IP-10, IFNγ, IL-2, IL-10, G-CSF, MIP1α, and TNF (widespread “cytokine storm”) [26, 27]. In fact, the inflammatory cytokine storm that marks the later stage of the disease in severe or critically ill patients, together with hypercoagulable state and decreased arterial blood oxygen tension, are closely related to the development of multiorgan damage including acute respiratory distress syndrome (ARDS), renal failure and cerebrovascular disease [28], and could also be associated with the retinal findings described in our study [29].

Importantly, the identification of viral RNA in cerebrospinal fluid in case reports [30] along with the presence of SARS-COV-2 spike protein receptor ACE2 in the central nervous system, particularly in vascular endothelium [9], requires us to consider the hypothesis of SARS-CoV-2 directly damaging CNS structures, including the retina. As well, an alternative host cell entry route through the receptor CD147 has been characterized [31], and a moderate to high expression of CD147 gene has been shown in human retina [32]. Moreover, positive RT-PCR has been reported in human retinal biopsies, suggesting that the viral genome may be directly infecting retinal neurons [15], and in other vertebrate species, specific coronavirus strains are able to infect retinal neurons both in vitro in retinal cell cultures [33] and in vivo after intravitreal inoculation of viral particles [34], causing a retinal degeneration named experimental coronavirus retinopathy (ECOR) [35, 36]. This has been shown to be a useful tool to experimentally model human progressive degenerations affecting photoreceptors and retinal pigment epithelium (RPE) [34]. In felines, coronavirus (feline infectious peritonitis virus or FIPV) is highly prevalent in the conjunctiva of infected animals, and may be associated with ophthalmological manifestations such as conjunctivitis, anterior uveitis, choroiditis with retinal detachment and retinal vasculitis [37].

A recent study specifically investigated neurologic involvement in hospitalized patients, noting that one-quarter of confirmed COVID-19 individuals had some manifestations of CNS affection [38]. Visual impairment was mentioned in 3% of patients, 2% being severe; The presence or absence of retinal changes was not documented.

Retinal lesions have been reported in outpatients after confirmed SARS-CoV-2 infection with mild to moderate symptoms, some of them characterized by non-specific and controversial hyper-reflective optical coherence tomography (OCT) lesions in the ganglion cell and inner plexiform layers, microhemorrhages and nerve fiber infarcts [20, 39], in addition to another report of two patients showing OCT lesions suggestive of paracentral acute middle maculopathy (PAMM) and acute macular neuroretinopathy (AMN), although a true association between the retinal pathologies and COVID-19 could not be made [40]. More recently, evaluation of 27 outpatients with retinal fundoscopy, B-scan OCT and OCT angiography at mean of 43 days after COVID-19 symptoms onset showed retinal microangiopathy manifested as cotton wool spots (clinical sign associated with nerve fiber infarcts) in 22% of patients [41].

Laboratorial parameters from blood samples have been shown in COVID-19 patients, such as D-dimer, ferritin and C-reactive protein. These were elevated in most of the patients in our study (Table 2). Hyperferritinemia is associated with several inflammatory conditions, such as sepsis, systemic inflammatory response syndrome (SIRS), multiorgan dysfunction syndrome.
(MODS), and macrophage activation syndrome (MAS). In critically ill patients, hyperferritine-
mia is associated with the severity of the underlying disease [42]. Elevation of D-dimer under-
lines an altered coagulation system with cascade dysregulation leading to thrombotic events
mostly associated with poor prognosis in COVID-19 [6]. Blood CRP and D-dimer have been
shown to be significantly higher in severe COVID-19 patients when compared to non-severe
cases [38]. In our study, there was no difference between groups (severe vs critical) on admi-
sion ferritin, D-dimer or CRP values (Table 2). Nevertheless, we need to study a larger number
of patients to gain sufficient statistical power for such comparisons [38].

A major strength of our study was the bedside retina documentation from confirmed
COVID-19 patients still hospitalized for clinical management of severe and critical disease.
Upon retina examination, patients were mostly in the inflammatory phase and so more likely
to present with systemic hypercoagulopathy, cytokine storm and blood clots formation in
small and large arterial vessels and in the venous system, leading to infarcts in several tissues
throughout the body, including myocardium, kidneys and lungs. In the CNS, acute cerebro-
vascular events, both ischemic or hemorrhagic, have been described in COVID-19 patients,
some of them reported as subclinical findings or even asymptomatic.

As a major limitation of this study, this was a small case series involving 47 eyes from 25
patients. In addition, retinal photography is not sensitive enough to detect small arteriolar or
capillary changes in the retinal circulation, nor to demonstrate discrete histological changes in
individual retinal layers. OCT, OCT-angiography, fluorescein angiography or electroretinogram
(ERG) may reveal subtle lesions. However, these are difficult tests that require much instrumen-
tation and their use in still hospitalized inpatients with droplet precaution is problematic and
largely infeasible. Another limitation is a likely underestimation of the number of retinal findings
as three patients from this series had the retinographies of only one eye evaluated: #13 and #25
did not consent to undergo pupil dilation, which lead to low image qualities in one of the eyes
due small pupil diameter; and #24, who at the time of retinal examination was in the pre-opera-
tive period for subarachnoid hemorrhage and had highly anisocoric pupils, so the examiner was
advised by the neurosurgery team to not induce pharmacological mydriasis in the miotic eye.

Conclusion
To the best of our knowledge, our study is the first to show that funduscopically evident retinal
vascular lesions such as flame-shaped or microhemorrhages and nerve fiber layer infarcts may
be present in not insignificant percentage of severe or critically ill COVID-19 patients during
their hospitalization. These retinal changes, only seen after morbid developments, were likely
secondary to clinical intercurrences or comorbidities, and may be important and easily acces-
sible outcome measures of therapeutic interventions and sentinels of neurologic and systemic
diseases during COVID-19 pandemic.

Acknowledgments
We give special thanks to Phelcom Technology Eyer for having generously lent one device for
this study group; to the physicians Vitor Delgado Mendes, MD, and Vinicius Vizeu Pereira
Alves, MD, for assisting with the electronic health records assessment; and to the NEURO-
COVID-RIO group for the useful and enlightening discussions about COVID-19 and neurology.

Author Contributions
Conceptualization: Rafael Lani-Louzada, Carolina do Val Ferreira Ramos, Ricardo Mello
Cordeiro.
Data curation: Rafael Lani-Louzada.

Formal analysis: Rafael Lani-Louzada, Carolina do Val Ferreira Ramos, Ricardo Mello Cordeiro, Alfredo A. Sadun.

Investigation: Rafael Lani-Louzada.

Methodology: Rafael Lani-Louzada, Carolina do Val Ferreira Ramos, Ricardo Mello Cordeiro, Alfredo A. Sadun.

Project administration: Rafael Lani-Louzada.

Validation: Rafael Lani-Louzada, Carolina do Val Ferreira Ramos, Alfredo A. Sadun.

Visualization: Carolina do Val Ferreira Ramos, Ricardo Mello Cordeiro, Alfredo A. Sadun.

Writing – original draft: Rafael Lani-Louzada, Carolina do Val Ferreira Ramos.

Writing – review & editing: Rafael Lani-Louzada, Carolina do Val Ferreira Ramos, Ricardo Mello Cordeiro, Alfredo A. Sadun.

References

1. Coronavirus disease (COVID-19) [Internet]. [cited 2020 Aug 29]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj0KCQow0r4BRClARIsAB_48MQMsHfJQpbPuEeMDqehDk38vRHbe3_TeLoGcLxYJbaTnpqFs7gaAqoBEALw_wCB.

2. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020; 35(5):1545–9. https://doi.org/10.1007/s11606-020-05762-w PMID: 32133578

3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID: 31986264

4. Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimer’s Dis. 2020; 76:1–17. https://doi.org/10.3233/JAD-200581 PMID: 32538857

5. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronavirus in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol. 2020; 1–10. https://doi.org/10.1001/jamaneurol.2020.2065 PMID: 32469387

6. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020; 127:104362. https://doi.org/10.1016/j.jcv.2020.104362 PMID: 3205883

7. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367(6485):1444–8. https://doi.org/10.1126/science.abb2762 PMID: 32132184

8. Hoffmann M, Kleine-Weber H, Krueger N, Mueller MA, Drosten C, Poeihmman S. The novel coronavirus 2019-nCoV uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv [Preprint]. 2020;2020.01.31.929042. https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1.

9. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203(2):631–7. https://doi.org/10.1002/path.1570 PMID: 15143377

10. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020; 9(1):1–7.

11. Liu L, Sun Y, Pan X, Shen W, Liu Z, Liu Y. Expression of SARS coronavirus S protein functional receptor—Angiotensin-converting enzyme 2 in human cornea and conjunctiva. Chin Ophthalmic Res [Internet]. 2004 [cited 2020 Jun 2]; 22:561–564. https://www.researchgate.net/publication/293355081_Expression_of_SARS_coronavirus_S_protein_functional_receptor_-_Angiotensin-converting_enzyme_2_in_human_cornea_and_conjunctiva.

12. Holappa M, Vapaatalo H, Vaajalanen A. Many Faces of Renin-angiotensin System—Focus on Eye. Open Ophthalmol J. 2017; 11(1):122–42. https://doi.org/10.2174/1874364101711010122 PMID: 28761586
13. Senanayake PDS, Drazba J, Shadrach K, Milsted A, Runger-Brandle E, Nishiya K, et al. Angiotensin II and its receptor subtypes in the human retina. Investig Ophthalmol Vis Sci. 2007; 48(7):3301–11. https://doi.org/10.1167/iovs.06-1024 PMID: 17591902

14. Wagner J, Danser AHJ, Derkx FH, De Jong PTVM, Paul M, Mullins JJ, et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: Evidence for an intracellular renin-angiotensin system. Br J Ophthalmol. 1996; 80(2):159–63. https://doi.org/10.1136/bjo.80.2.159 PMID: 8814748

15. Casagrande M, Fitzek A, Püscher K, Aleshcheva G, Schultheiss H-P, Berneking L, et al. Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients. Ocul Immunol Inflamm. 2020 Jul 3; 28(5):721–725. https://doi.org/10.1080/09273948.2020.1770301 PMID: 32469258

16. Dowling JE. The retina: an approachable part of the brain. Belknap Press of Harvard University Press; 2012: 355 p.

17. Medicine NHC& NA of TC. Diagnosis and Treatment Plan for COVID-19 (Trial Version 7). Chin Med J (Engl). 2020; 133(9):1087–95.

18. World Health Organization (WHO). Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19) and considerations during severe shortages. Who [Internet]. 2020;(April):1–28. https://apps.who.int/iris/handle/10665/331695.

19. Chanchalani G, Jiandan P, Ansari AS, Mehta S. The prevalence of retinal lesions in septic ICU patients-a cross-sectional, observational study. Intensive Care Med Exp. 2015 Dec; 3(Suppl 1):A875. https://doi.org/10.1186/2197-425X-3-S1-A875

20. Marinho PM, Marcos AAA, Romano AC, Nascimento H, Belfort R Jr. Retinal findings in patients with COVID-19. Lancet. 2020; 395(10237):1610. https://doi.org/10.1016/S0140-6736(20)31014-X PMID: 32405105

21. Gklinos P. Neurological manifestations of COVID-19: a review of what we know so far. J Neurol. 2020 May 26:1–5. https://doi.org/10.1007/s00415-020-09939-5 PMID: 32458197

22. Dinkin M, Gao V, Kahan J, Bobker S, Simonetto M, Wechsler P, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020 Aug 4; 95(5):221–223. https://doi.org/10.1212/WNL.00000000009700 PMID: 32358218

23. Zanin L, Saraceno G, Panciani PP, Renisi G, Signorini L, Migliorati K, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien). 2020; 1–4.

24. Gutierrez-Ortiz C, Mendez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020 August 4; 95 (5): e601–e605. https://doi.org/10.1212/WNL.00000000009619 PMID: 32303650

25. Pugin D, Vargas M-I, Thieffry C, Schibler M, Grosquelin O, Pugin J, et al. COVID-19-related encephalopathy responsive to high doses glucocorticoids. Neurology. 2020 September 22; 95 (12): 543–546. https://doi.org/10.1212/WNL.000000000010354 PMID: 32680950

26. Lai C, Ko W, Lee P, Jean S, Hsueh P. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents. 2020 Aug; 56(2):106024. https://doi.org/10.1016/j.ijantimicag.2020.106024 PMID: 32450197

27. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Jun; 20(6):363–374. https://doi.org/10.1038/s41577-020-0311-8 PMID: 32346093

28. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J Infect. 2020 Jun; 80(6):607–613. https://doi.org/10.1016/j.jinf.2020.03.037 PMID: 32283152

29. Raony I, Saggioiro de Figueiredo C. Retinal outcomes of COVID-19: Possible role of CD147 and cytokine storm in infected patients with diabetes mellitus. Diabetes Res Clin Pract. 2020 Jul; 165:108280. https://doi.org/10.1016/j.diabres.2020.108280 PMID: 32592839

30. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020 May; 94:55–58. doi.org/10.1016/j.ijid.2020.03.062 PMID: 32251791

31. Wang K, Chen W, Zhou Y-S, Lian J-Q, Zhang Z, Du P, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. BioRxiv [Preprint]. 2020 [Posted March 14, 2020]. https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1

32. Hamashima K, Gautam P, Lau KA, Khiong CW, Blenkinsop TA, Li H, et al. Potential modes of COVID-19 transmission from human eye revealed by single-cell atlas. BioRxiv [Preprint]. 2020 [Posted May 10, 2020]. https://www.biorxiv.org/content/10.1101/2020.05.09.085613v2

33. Wang Y, Detrick B, Hooks JJ. Coronavirus (JHM) replication within the retina: Analysis of cell tropism in mouse retinal cell cultures. Virology. 1993 Mar 1; 193(1):124–37. https://doi.org/10.1006/viro.1993.1109 PMID: 8382393
34. Robbins SG, Hamel CP, Detrick B, Hooks JJ. Murine coronavirus induces an acute and long-lasting disease of the retina. Lab Investig. 1990 Apr; 62(4): 417–26. PMID: 2159082

35. Detrick B, Lee MT, Chin MS, Hooper LC, Chan CC, Hooks JJ. Experimental coronavirus retinopathy (ECOR): Retinal degeneration susceptible mice have an augmented interferon and chemokine (CXCL9, CXCL10) response early after virus infection. J Neuroimmunol. 2008 Jan; 193(1–2):28–37. https://doi.org/10.1016/j.jneuroim.2007.09.032 PMID: 18037505

36. Chin MS, Hooper LC, Hooks JJ, Detrick B. Identification of α-fodrin as an autoantigen in experimental coronavirus retinopathy (ECOR). J Neuroimmunol. 2014 Jul 15; 272(1): 42–50. https://doi.org/10.1016/j.jneuroim.2014.05.002 PMID: 24864013

37. Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm. 2020; 28(3): 391–5. https://doi.org/10.1080/09273948.2020.1738501 PMID: 32175797

38. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020 Jun 1; 77(6):683–690. https://doi.org/10.1001/jamaneurol.2020.1127 PMID: 32275288

39. Vavvas DG, Sarraf D, Sadda SR, Elliott D, Ehlers JP. Concerns about the interpretation of OCT and fundus findings in COVID-19 patients in recent Lancet publication. Eye (Lond). 2020 Jul 9; 8–9. https://doi.org/10.1038/s41433-020-1084-9.

40. Virgo J, Mohamed M. Paracentral acute middle maculopathy and acute macular neuroretinopathy following SARS-CoV-2 infection. Eye (Lond). 2020 Jul 3: 1–2. https://doi.org/10.1038/s41433-020-1069-8 PMID: 32620843

41. Landecho MF, Yuste JR, Gandara E, Sunundegui P, Quiroga J, Alcaide AB, et al. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease? J Intern Med. 2020; 1–5. https://doi.org/10.1111/joim.13156

42. Rosário C, Zandmann-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The Hyperferritinemic Syndrome: Macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013 Aug 22; 11:185. https://doi.org/10.1186/1741-7015-11-185 PMID: 23968282